Danish pharmaceutical firm Novo Nordisk has launched a new product
in its Norditropin range of human growth hormone (hGH) that
simplifies the delivery of the drug to children with growing
difficulties.
Danish pharmaceutical company Novo Nordisk has decided to put its
weight behind the inhaled insulin project it has been pursuing
alongside US drug delivery specialist Aradigm.
News that B-MS has dropped out of an agreement to develop Basulin,
an improved formulation of insulin which was the subject of a $165
million deal - including $20 million upfront - between the two
companies last year.
Belgium's Opperbas Holding has started a mid-stage clinical trial
of a new formulation of factor VIII - used to treat haemophilia A -
that should cut the number of injections that sufferers of the
bleeding disease need to endure.
Novo Nordisk has broken ground on a new manufacturing facility in
Kalundborg, Denmark, that will produce liraglutide, a potential new
product for treating type 2 diabetes.
Denmark's Novo Nordisk has signed a €47m deal with Neose to develop
long-acting versions of three protein drugs using a proprietary
PEGylation technology.
Danish chemical group Novo Nordisk will likely deliver a
'lacklustre' set of results for the first nine months of the year
but strong enough to put the company on track to deliver its
guidance of 'low single-digit EBIT...
Danish Novo Nordisk plans to break ground on a €10 million
expansion of its insulin manufacturing facility in Clayton, US. The
company has awarded the contract to BE&K Engineering and Suitt
Construction for the 19,000-square-foot...